



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>A61K 31/385</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 99/44603</b></p> <p>(43) International Publication Date: 10 September 1999 (10.09.99)</p>
<p>(21) International Application Number: PCT/US99/04879</p> <p>(22) International Filing Date: 5 March 1999 (05.03.99)</p> <p>(30) Priority Data: 60/077,092                      6 March 1998 (06.03.98)                      US</p> <p>(71)(72) Applicant and Inventor: SPONSEL, William, E. [US/US]; 19733 La Sierra, San Antonio, TX 78256 (US).</p> <p>(74) Agent: SISSON, Thomas, E.; Suite 1650, 300 Convent Street, San Antonio, TX 78205 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: COMPOSITION AND METHOD FOR TREATING MACULAR DISORDERS</p>		
<p>(57) Abstract</p> <p>A method and composition for treating macular disorders. A pharmacologically effective amount of a carbonic anhydrase inhibitor is combined with a pharmacologically effective amount of an ocular hypotensive agent sufficient to improve visual function.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1           **TITLE: COMPOSITION AND METHOD FOR TREATING MACULAR DISORDERS**

2

3

4                           **BACKGROUND OF THE INVENTION**

5           **1.     Field of The Invention**

6                   Applicant's invention relates to a composition and method for treating certain ocular  
7 disorders and, particularly, macular edema and macular degeneration through the application of  
8 a topical carbonic anhydrase inhibitor and an ocular hypotensive agent or inotropic agents in an  
9 amount sufficient to improve visual function. Other macular disorders that can be treated are  
10 familial drusen, and macular disorders related to hypertension, angioma, papillitis, neuro retinitis  
11 (including Lebers stellate retinopathy) and other pigmentary retinal degenerative disorders.

12           **2.     Background Information**

13                   Macular edema is swelling within the retina in the critically important central visual zone  
14 at the posterior pole of the eye. An accumulation of fluid tends to distract the retinal neural  
15 elements from one another and from their local blood supply, creating a dormancy of visual  
16 function in the area. Usually, the process is self-limiting, but occasionally permanent visual  
17 disability results from macular edema. Often times, the swelling may take many months to clear.  
18 The precise mechanism by which swelling is triggered is uncertain, but it is probable that certain  
19 natural metabolic toxins may play an important role in the disease process. Macular swelling  
20 may also follow the insertion of artificial lens implants and cataract surgery, particularly if there  
21 is a breach in the lens capsule which segregates the vitreous gel from the fluid-filled anterior  
22 chamber. Longstanding macular edema after cataract surgery is one of the most frustrating  
23 dilemmas in all of ophthalmology, and is remarkably common.

1           Macular edema is a common and alarming ocular problem, for which no useful form of  
2 therapy has been previously known.

3           Two types of cystoid macular edema are:

- 4           a.       Those without vascular leakage: retinitis pigmentosa and other pigmentary retinal  
5                   degenerative disorders, early stage macular hole, and choroidal neovascularization;  
6                   and  
7           b.       Those with vascular leakage: diabetic retinopathy; branch retinal vein occlusion;  
8                   intermediate uveitis; and ideopathicretinaltelangiectasis.

9           Another even more common chronic condition, which has typically been presumed to be  
10 irreversible, is macular degeneration. Instead of fluid accumulating in the outer retina, hard  
11 accumulations of lipofuscin, a metabolic waste product, tend to accumulate between the  
12 photoreceptors and the villi of the retinal pigment epithelium. These accumulations gradually  
13 enlarge, and in their early pathologic phase create discrete accumulations known as drusen. The  
14 lipofuscin is believed to accumulate as a result of the breaking off of the photoreceptor elements.  
15 Shedding of the cellular components of the photoreceptors is constantly occurring in a healthy  
16 retina. Good retinal pigment epithelial metabolism generally ensures a rapid clearance of such  
17 catabolic by-products of vision. The accumulation of this waste material retards the interaction  
18 between the retina and the retinal pigment epithelium from which nutrients arrive and through  
19 which catabolites are cleansed establishing a vicious cycle of catabolite accumulation. The  
20 accumulations not only block metabolic transfer between the retina and retinal pigment  
21 epithelium; they actually continue to undergo photoresponsive metabolism, constantly wasting  
22 precious NADH reducing power with no benefit.

23           An improved local circulation or a stabilization of membrane pH gradients might retard

1 or prevent the accumulation of lipofuscin and break the vicious cycle of progressive blockage  
2 and waste of metabolic products passing to and from the retina.

3 As drusen accumulate in number and begin to coalesce, vast areas of retinal  
4 photoreceptors may become permanently disengaged from their neighboring retinal pigment  
5 epithelial villi. The sections of retina so affected become blind. Sadly, the greatest propensity  
6 among the aging population is for drusen to accumulate in the very central area of vision, the  
7 macula. Macular degeneration is the most common cause of legal blindness in the United States  
8 and Europe.

9 Acetazolamide, a carbonic anhydrase inhibitor, has been given orally to treat macular  
10 edema but, while helpful, produces unpredictable responses and characteristically generates many  
11 systemic side effects. Even with the lower doses used in treatment of macular edema, the  
12 experience of physicians using acetazolamide (Diamox®) has been far from gratifying, with the  
13 large proportion of patients failing to continue therapy because of poor drug tolerance.

14 Currently, zinc in tablet form is administered to treat macular edema, but is also not  
15 effective and lacks any substantive clinical scientific support.

16 Whereas macular edema typically affects only one eye, macular degeneration typically  
17 involves both eyes and is usually fairly symmetric in its presentation and progression. There is  
18 virtually no family of European heritage in America without some relative who has suffered  
19 progressive loss of vision in their latter years as a result of macular degeneration. The problem  
20 is on the rise, and will continue to mount as the baby boom generation progresses towards  
21 maturity.

22 Macular disease afflicts a small area of the very central retina, an area critical for reading  
23 and color vision. This is an area not typically affected to any practical extent by the disease

1 glaucoma, which tends to diminish the surround vision (that is, the peripheral retina). This  
2 distinction is important, since the present invention is based upon the novel use of drugs currently  
3 used in the treatment of glaucoma.

4 It is important to understand that the retina is essentially a specialized part of the brain,  
5 and its circulation is very tightly regulated. Blood flow through the brain is typically constant  
6 in healthy individuals, whether running a marathon or sleeping. Obviously, huge variations in  
7 the inflow pressure of carotid artery blood to the brain occur throughout a typical day, and the  
8 vasculature in the cerebral cortex responds by adjusting its resistance. This is accomplished by  
9 constriction or dilation of the vessels throughout the brain. If the cerebrospinal fluid pressure  
10 is increased, creating, in effect, a stiffer vascular bed in the cerebral cortex, the blood vessels in  
11 the brain dilate to reduce intrinsic resistance, maintaining constant blood flow. This process is  
12 called autoregulation.

13 Autoregulation in the retina is analogous to that found in the brain, so if intraocular  
14 pressure is reduced, circulation in the retina is not necessarily increased. This point is clearly  
15 illustrated as a coincidental feature of two of the cases provided herein. Hyperventilation (to  
16 blow off carbon dioxide and thereby reduce circulation to all the intrinsic vessels of the eye), or  
17 treatment with latanoprost (increasing the flow of clear fluid out of the eye) both produced  
18 significant eye pressure reduction, but visual function was actually simultaneously diminished.  
19 In each instance, however, if dorzolamide was coadministered there was visual enhancement.

20 Dorzolamide's profound effect on circulation is clearly not the result of any effect the  
21 drug might have on eye pressure, but arises as a result of its interference with autoregulation in  
22 the eye. The drug produces greater vascular compliance (that is to say, vessels remain effectively  
23 wide open even when other factors present would tend to produce vasoconstriction). In

1 practice, drugs which reduce eye pressure tend to produce minimal changes in circulation and  
2 vision, and may in certain instances actually diminish both. It was discovered, quite  
3 unexpectedly, that a range of agents which reduce eye pressure, even those known to produce  
4 visual decrease while reducing pressure, can have a powerfully positive effect on both circulation  
5 and vision when dorzolamide is coadministered. The effects of this combination therapy appear  
6 to be profound.

7 In essence, once dorzolamide has uncoupled the autoregulatory system, which tends to  
8 balance changes in perfusion pressure with compensatory changes in intrinsic vascular tone,  
9 additional alterations in the perfusion pressure gradient (whether induced pharmacologically or  
10 by physiologic perturbation) are accompanied by a concomitant and corresponding change in  
11 retinal blood flow. There is no precedent for such a finding in the ophthalmological literature.  
12 The ability to uncouple autoregulation, manipulate perfusion pressure, and realize a  
13 corresponding physiologic effect opens up the potential for designing a range of specific  
14 treatments for a variety of retinal diseases.

#### 15 SUMMARY OF THE INVENTION

16 U.S. Patent App. Ser. No. 08/445,899, filed May 22, 1995, and Ser. No. 08/806,866 filed  
17 February 25, 1997, which are incorporated herein by reference, disclose treatment of macular  
18 disorders by increasing ocular blood flow via application of a topical carbonic anhydrase inhibitor  
19 (TCAI). The treatment disclosed there is independent of intraocular pressure.

20 The instant invention applies the discovery that macular disorders may be remarkably and  
21 unexpectedly more effectively treated if the TCAI is applied in combination with an ocular  
22 hypotensive agent. The likely mechanism for this result is that the ocular hypotensive agent  
23 permits an increased ocular perfusion pressure which in turn multiplies the beneficial increased

1 blood flow effect of the TCAI. The improvement in vision or stabilization of the macular  
2 disorder caused by applying the TCAI and hypotensive agent in combination exceeds any  
3 expected improvements that would be caused by the TCAI and hypotensive agent if their effect  
4 was merely additive. Nothing in the existing literature on the treatment of glaucoma, nor in any  
5 anecdotal record, FDA submission or prior patent would have led one to expect the findings  
6 outlined below.

7 The present invention overcomes the problems of the prior art and provides an effective  
8 method for increasing retinal blood flow and particularly for treating macular disorders, most  
9 particularly macular edema and macular degeneration.

10 Briefly stated, the present invention comprises increasing vascular perfusion by applying  
11 a pharmacologically effective amount of a topical carbonic anhydrase inhibitor in combination  
12 with an ocular hypotensive agent or inotropic agent either to the eye or systemically. The  
13 present invention also comprises a method of treating macular edema and macular degeneration  
14 comprising the application to an affected eye of a topical carbonic anhydrase inhibitor in  
15 combination with an ocular hypotensive agent or inotropic agent, in an amount effective to  
16 ameliorate the macular edema or macular degeneration.

17 The instant invention provides an effective treatment for maintaining the health of the eye  
18 and effectively treating macular edema, macular degeneration, and other eye conditions by  
19 improved vascular perfusion in the retina of the eye.

20 This method for treating or preventing macular edema, macular degeneration, retinopathy  
21 of prematurity or any ocular disorder the etiology of which is clinically acknowledged to be  
22 partially or completely based upon inadequate vascular perfusion, comprises applying to the eye  
23 a pharmologically effective amount of a topical carbonic anhydrase inhibitor in combination with

1 an ocular hypotensive agent or inotropic agent. The carbonic anhydrase inhibitor may be a  
2 dorzolamide or brinzolamide and the ocular hypotensive agent or inotropic agent may be a beta  
3 blocker, adrenergic agonist, miotic, prostaglandin, and the like. The carbonic anhydrase inhibitor  
4 in combination with the ocular hypotensive agent or inotropic agent may be applied once daily  
5 to the eye or twice daily to the eye.

6 The carbonic anhydrase inhibitor may be administered as a 0.01-5%, preferably a 0.5 to  
7 2% solution or suspension and the ocular hypotensive agent as a 0.001% to 6.0% solution or  
8 suspension in an ophthalmologically acceptable carrier. Such agents include, but not be limited  
9 to beta blockers (betaxolol, timolol, optipranolol, levobunolol, metapranolol, carteolol, and the  
10 like), miotic agents (pilocarpine, carbachol, phospholine iodide, and the like), adrenergic agonists  
11 (iopidine, brimonidine, epinephrine, dipivephrin, and the like), prostaglandin derivatives  
12 (latanoprost and the like), and related compounds directed toward the reduction of intraocular  
13 pressure, plus agents effective in the enhancement of carotid perfusion pressure, including a  
14 range of oral and sublingual systemic drugs intended to improve cardiac contractility or decrease  
15 carotid or ophthalmic arterial vascular resistance.

#### 16 **BRIEF DESCRIPTION OF THE DRAWINGS**

17 Fig. 1A is a correlation graph of retinal circulation as measured by Heidelberg Retinal  
18 Flowmetry (HRF) with dorzolamide.

19 Fig. 1B is a correlation graph of retinal circulation as measured by Heidelberg Retinal  
20 Flowmetry (HRF) with a placebo.

21 Fig. 2 is a correlation graph of IOP (hyperventilation) versus 4 cpd contrast sensitivity.

22 Fig. 3 is a correlation graph of IOP (hypercapnia) versus Humphrey Visual Field (HFA).

23 Fig. 4 is a graph showing changes from a baseline in visual function responses in both

1 eyes as measured by Humphrey perimeter.

2 Fig. 5 illustrates a Humphrey 30-2 visual field report of the patient in Example 3.

3 Fig. 6 illustrates a 10-degree visual field of the same patient at the start of the test in  
4 Example 3.

5 Fig. 7 shows the visual fields of the patient of Example 3 prior to the fields of Fig. 5.

6 Fig. 8 shows the follow up visual field of the patient of Example 3, after treatment with  
7 the method and a composition of the present invention.

8 Fig. 9 shows the right visual field of the patient in Example 4 prior to treatment.

9 Fig. 10 illustrates the right visual field of the patient in Example 4 after treatment with  
10 the method and another composition of the present invention.

### 11 **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT**

12 The instant invention is grounded on the discovery that increasing vascular perfusion in  
13 the retina of the eye is a safe and effective way to maintain the health of the eye and to treat an  
14 ocular disorder which is based on inadequate vascular perfusion such as macular edema and  
15 macular degeneration. While the precise theory is not completely understood, it is believed that  
16 improved (i.e., increased) vascular perfusion in the retina of the eye greatly improves optic nerve  
17 health which, in turn, effectively combats macular edema and macular degeneration and other  
18 ocular disorders.

19 Circulation in the retina is highly pH-dependent. Studies in which various gases are  
20 introduced via the respiratory system into the blood stream clearly demonstrate that as the CO<sub>2</sub>  
21 level increases and pH decreases, circulation to the retina typically increases by upward of 40%  
22 from the baseline level observed during breathing of atmospheric air. Conversely, breathing pure  
23 oxygen produces a profound decrease in circulation in the retina. This latter response may be

1 in part responsible for the disease process known as retrolental fibroplasia, or retinopathy of  
2 prematurity, which causes total or partial blindness in many premature infants.

3 The therapeutic use of oxygen in the treatment of neonatal premature infants may thus  
4 lead to blindness by inducing maldevelopment of the retinal arterial tree. It is very likely that this  
5 developmental flaw is promoted by vasospasm in the retinal vasculature. Very premature infants  
6 may develop similar problems when exposed to atmospheric levels of oxygen before their ocular  
7 tissues are ready.

8 It has been found that a safe and effective way to increase vascular perfusion in the retina  
9 of the eye is the application thereto of a TCAI.

10 TCAIs are well known for use in lowering intraocular pressure in treating glaucoma.  
11 Specific examples are acetazolamide, methazolamide, dorzolamide, pharmacologically active  
12 salts thereof, and the like. These and other TCAIs are set forth in U.S. Patent Nos. 4,386,098;  
13 4,416,890; 4,426,388; 4,797,413; and 5,153,192; and are specifically incorporated herein by  
14 reference. Of these, dorzolamide and brinzolamide are preferred.

15 The TCAI are aromatic sulfonamides and can be used in the form of solutions, ointments,  
16 gels, or other topical ophthalmic preparations prepared with conventional amounts of  
17 conventional pharmacologically acceptable carriers, excipients, preservatives, and buffering  
18 agents conventionally used in preparing topical ophthalmic preparations.

19 Dorzolamide hydrochloride is a topically applied carbonic anhydrase inhibitor with a well  
20 established ocular hypotensive action. The drug is a powerful inhibitor of carbonic anhydrase  
21 in the ciliary epithelium, and is believed to have a similar effect on the anatomically contiguous  
22 neuroretina and its pigment epithelium. As such, the drug sequesters CO<sub>2</sub> and effects a reduction  
23 in pH within or adjacent to the retinal and choroidal vascular beds. Human experimental results

1 show that dorzolamide may selectively enhance visual function and retinal perfusion.

2 Ocular circulation, like that of the cerebral cortex, is strongly influenced by ambient  
3 carbon dioxide. An increase in CO<sub>2</sub> in the blood is associated with an increase in retinal blood  
4 flow. Carbonic anhydrase is a ubiquitous and highly active enzyme which is responsible for CO<sub>2</sub>  
5 transfer and metabolism. Dorzolamide's efficacy in reducing intraocular pressure results from  
6 its ability to exceed a threshold of >99% enzyme inhibition at the level of the ciliary body, the  
7 site of aqueous humor production. Thus, sustained uveal penetration of the drug is required for  
8 any ocular hypotensive effect. Vascular responsiveness to CO<sub>2</sub>, which is a more graded  
9 phenomenon, would be expected in tissues adjacent to the ciliary body, with potentiation of both  
10 perfusion (via vasodilation) and oxygen transfer (via the Bohr effect), since carbonic anhydrase  
11 is present throughout the uveal system and retinal pigment epithelium.

12 It will be evident that the amount of TCAI in the ophthalmic preparation can vary widely  
13 dependent mainly upon the age of the patient and type of ocular disorder. Effective amounts of  
14 the TCAI can vary from a 0.01 to 5% solution, preferably 0.5 to 2%.

15 In like manner, treatment will vary from 1 to 2 or more topical applications daily  
16 dependent mainly on the severity of the ocular disorder being treated.

17 The invention will be further described in connection with the following example which  
18 is set forth for purposes of illustration only.

#### 19 Example 1

20 Twelve consenting healthy adults (5 males and 7 non-pregnant, non-lactating females)  
21 all having intraocular pressures below 21mm Hg and symmetric cup/disc ratios of 0.4 or less,  
22 were recruited for study under an institutional review board approved protocol. General  
23 exclusion criteria comprised (1) history of any systemic disease such as hypertension, diabetes,

1 asthma, or vascular disorders, (2) pregnant or nursing women, or women planning a pregnancy,  
2 (3) participation in any drug research study within 30 days prior to entry into this study, or  
3 concurrent participation in any other research study, (4) chronic alcohol abuse, chronic drug  
4 abuse, concurrent tobacco use in any form, or use of illicit drugs, (5) drug therapy of any kind  
5 (including aspirin or platelet-active agent) within 2 weeks of entering the study, (6) any clinically  
6 significant acute health exacerbation (e.g., viral infection), recurrent or newly diagnosed  
7 condition or dysfunction which has not been stabilized or might require treatment of any kind,  
8 (7) any hematologic abnormality, and (8) history of hypersensitivity to sulfonamide drugs.  
9 Ophthalmic exclusive criteria were: (1) use of contact lenses within 12 hours of study entry, (2)  
10 any history of intraocular disease, (3) any active external ocular disease, infection, or uveitis, (4)  
11 corneal abnormalities, (5) asymmetry of intraocular pressure of more than 5mm Hg between  
12 eyes, (6) gonioscopic evidence of angle narrowing, (7) ocular or visual symptoms, including  
13 photophobia, photopsia, metamorphopsia, diplopia, or transient visual loss, (8) history of  
14 hypersensitivity to any topical ocular agent, (9) media opacities, (10) corrected visual acuity  
15 worse than 20/25 in either eye, and (11) astigmatism of >1.5 diopter in either eye.

16 The study was of double-masked, placebo-controlled, single-center, crossover design,  
17 to assess the effects of carbon dioxide on the visual function of 12 healthy adults, and to observe  
18 for any modulating effects of 2% dorzolamide under conditions of normal breathing, physiologic  
19 hypercapnia (with accompanying carbon dioxide tissue loading), followed rapidly by physiologic  
20 hypocapnia. Inclusion and exclusion criteria were rigidly enforced, and there was no subject  
21 attrition throughout the study.

22 Identical 5ml ocumeter bottles containing either dorzolamide 2% or placebo were  
23 provided to each subject according to a randomized allocation schedule, the code of which was

1 not revealed until the study was complete. Treatment was applied, one drop three times daily,  
2 to the right eye only. Six subjects received dorzolamide for 4 days, followed by a two-week  
3 washout period and then 4 days of placebo; six subjects received placebo eyedrops for 4 days,  
4 and a two-week washout followed by 4 days of dorzolamide.

5 A pre-study examination was conducted on each subject within 7 days of study entry  
6 during which the following was documented: ophthalmic and general history, visual acuity,  
7 external slit lamp examination, tonometry by pneumotonometer (Mentor), dilated  
8 ophthalmoscopy, Humphrey 10-2 visual field, NeuroScientific 8010 two-alternative forced  
9 choice staircase contrast sensitivity testing (1 and 4 cycles per degree vertical sinusoidal gratings;  
10 square wave temporal modulation at 7.5Hz presented on a black and white monitor, subtending  
11 7.5 degrees at the 1.22m viewing distance fixed by a chin-head rest; 82 cd/m<sup>2</sup> space-averaged  
12 luminance at the screen), blood pressure, and heart rate. Blue field entoptic perimacular  
13 leukocyte velocity and density, scanning laser video fluorescein angiography, and Heidelberg  
14 scanning laser retinal flowmetry were also performed for related studies. All females of  
15 childbearing potential performed B-HCG pregnancy testing, and all were found to be negative.

16 Qualifying subjects were instructed in eyedrop application technique, and instilled one  
17 drop of study medication to the right eye at 8:00 a.m., 4:00 p.m., and at bedtime each day  
18 throughout the study period. At 9:00 a.m. on day 2 of each study phase, contrast sensitivity was  
19 measured in both eyes. At 9:30 a.m., subjects commenced inhaling a mixture of 5% CO<sub>2</sub> in air  
20 through a sealed mouthpiece on a Rudolf valve system from a single premixed tank until the end-  
21 tidal CO<sub>2</sub> level was 15+/-2.5% above the starting level for at least 15 minutes. Blood pressure,  
22 pulse, and contrast sensitivity at the two spatial frequencies were measured while the subject  
23 continued to breath the gas mixture, followed by measurement of intraocular pressure. Subjects

1 then commenced hyperventilating room air to the beat of a metronome until the CO<sub>2</sub> of their  
2 expired air was 15+/-2.5% below the initial baseline value for 15 minutes. All of the  
3 aforementioned measurements were obtained as the subject continued to hyperventilate.

4 On day 2, together with bilateral contrast sensitivity testing, each subject underwent  
5 studies of midperipheral retinal microcirculation in both eyes using the Heidelberg retinal  
6 flowmeter, avoiding any visible vessels, as described elsewhere. Similarly, each subject  
7 underwent, in the treated eye only, video fluorescein angiography using the Scanning Laser  
8 Ophthalmoscope (Rodenstock/Canon), to determine arteriovenous passage time (AVP;  
9 determined by finding the difference between the time of appearance of the dye in the  
10 peripapillary retinal arterioles and its reappearance in their corresponding veins) and capillary  
11 transit velocity (CTV; calculated by timing the passage of hypofluorescent particles through  
12 perifoveal capillaries).

13 On day 3, having continued the topical treatment three times daily to the right eye, each  
14 subject underwent perimacular leukocyte velocity and density studies in both eyes using the  
15 Oculix Blue Field simulation technique. Three sets of circulatory measurements were obtained  
16 under baseline (9:00 a.m.), CO<sub>2</sub> supplementation (9:45 a.m.) and hyperventilation (10:30 a.m.)  
17 conditions, as above, with the other concomitant physiologic measures and intraocular pressure  
18 also being monitored. At the conclusion of the study, subjects were instructed to discontinue  
19 topical treatment for 2 weeks, and were scheduled to return for an identical series of studies  
20 while using their second phase masked topical agent. Subjects were instructed not to use any  
21 ophthalmic or systemic medications during the washout period. A detailed protocol for  
22 monitoring and recording any adverse experiences, with appropriate case report forms, was  
23 employed throughout the study; no significant adverse experiences were encountered throughout

1 the study.

2 Upon completion of both phases in all 12 subjects, statistical analysis was carried out to  
3 determine whether circulatory measures differed (under normal breathing conditions,  
4 hypercapnia, or hyperventilatory hypocapnia) while subjects were receiving dorzolamide from  
5 when they were receiving placebo. Similar comparisons were made between the treated right  
6 eye and untreated left eye. In addition, correlation studies were performed to elicit any  
7 significant associations which might exist between ocular perfusion and intraocular pressure  
8 changes. Comparisons were by standard 2-tailed t-test, and correlations by obtaining Pearson  
9 R values and Spearman Rank correlation probability analysis.

10 It is known from prior analysis that dorzolamide enhances visual function and that vision  
11 responses are closely associated to retinal circulation (HRF in Figs. 1A and 1B) when the drug  
12 is present, but not in its absence. Mean intraocular pressure did not differ significantly with  
13 either dorzolamide or placebo treatment from pretreatment baseline values among these healthy,  
14 tonometrically normotensive subjects.

15 A more detailed analysis of study data discloses a series of second order associations not  
16 previously known to exist between the extent of intraocular pressure change and visual function  
17 during dorzolamide therapy (Figures 2 and 3). These findings are most unexpected. Variable  
18 intraocular pressure responses arose among individuals in the study population under both  
19 hypercarbia and hyperventilation, the latter condition tending to result in both IOP and visual  
20 decrease among nearly all subjects.

21 Any effect dorzolamide may otherwise have exerted on the intraocular pressure per se  
22 among these normal eyes was overwhelmed by intraocular pressure effects of the gas  
23 perturbations. Yet, despite the absence of any significant drug-induced ocular hypotensive

1 response, a series of remarkable secondary associations involving intraocular pressure changes,  
2 induced by the respiratory maneuvers, emerged upon close examination of the correlation data,  
3 but only when dorzolamide was present. As with the previous visual function analysis, no  
4 evidence was noted in the perfusion studies of any systemic pharmacologic crossover effect of  
5 topical dorzolamide to the nontreated fellow eye.

6 It should be understood that the eye has two largely independent circulatory systems,  
7 retinal and uveal. The retinal circulation accounts for only 2% of total eye circulation, but this  
8 2% is critical to the health of the eye's "wiring" to the brain, i.e., the 1.2 million axons which  
9 make up the nerve trunk known as the optic nerve. The cell bodies containing the genetic  
10 material and metabolic machinery for these "wires" are all located in the inner layer of the retina,  
11 and derive virtually all their energy supply from the locally autoregulated retinal circulation. Any  
12 significant compromise to the retinal circulation is typically accompanied by visual loss.

13 In contradistinction, the majority of the eye's inner circulation passes through the uveal  
14 system, a spongelike, erectile tangle of vessels which lies behind the retina and its pigment  
15 epithelium. This vascular bed provides a rich supply of nutrients to the metabolically active  
16 photoreceptors of the outer retina, and the pigment epithelium which supports them. Moreover,  
17 this seemingly excessive blood supply acts as a heat sink to absorb thermal energy from focused  
18 light which could otherwise damage neural tissues.

19 The choroidal circulation, the part of the uveal vascular bed lying directly behind the  
20 retina, has some local regulation characteristics, but is also supplied with autonomic nerves  
21 capable of producing major changes in circulatory volume in response to stimuli -- not  
22 necessarily even generated in the eye itself.

23 In healthy eyes, because of the choroid's relative abundance of vessels, fairly large

1 changes in choroidal blood flow may be accompanied by minimal visual function change.  
2 However, since the uveal circulation comprises a significant portion of the ocular volume, a  
3 substantial drop in choroidal blood flow is generally accompanied by a significant decrease in  
4 intraocular pressure. Thus, during hyperventilation, when the natural vasodilator carbon dioxide  
5 is blown off, both choroidal and retinal circulation decrease in tandem, and visual function  
6 correspondingly diminishes. Typically, among the study group, an individual with a large  
7 intraocular pressure decrease would have a very large visual function deficit during  
8 hyperventilation.

9 Administration of dorzolamide, which is known to penetrate rapidly to the retina, would  
10 be expected to effect the sequestration of carbon dioxide in the back of the eye by blocking the  
11 enzyme responsible for its clearance from both the retina and choroid. The very volume of the  
12 local circulation in the choroid would be expected to clear the drug from that tissue more rapidly  
13 than from the retina. Thus, during hyperventilation the relative effects on vascular tone of  
14 dorzolamide would be expected to be greater in the retina than within the choroid, all other  
15 factors being equal. The independent autonomic nerve supply to the choroid allows its vessels  
16 to constrict in response to elimination of carbon dioxide throughout the body, while retinal blood  
17 flow is dictated by local changes only. Thus, despite dorzolamide therapy, hyperventilation still  
18 produces an intraocular pressure decrease as a consequence of uveal vasoconstriction, since that  
19 system comprises the majority of the ocular circulatory volume.

20 Individuals with a large pressure drop, who tended to have the greatest visual loss during  
21 placebo treatment, produced large pressure drops during dorzolamide therapy, but had much  
22 more positive visual function responses. In essence, their relaxed retinal vasculature was able  
23 to exploit the choroidal vasoconstriction and accompanying pressure reduction in the eye, with

1 improved perfusion pressure producing a noncompensated retinal circulation increase. This  
2 study evidenced that a physiologic stimulus classically associated with pressure reduction and  
3 visual loss could, in the presence of a TCAI, actually produce visual benefit.

4 Dorzolamide treatment in Example 1 was associated with a stabilization of retinal  
5 perfusion during both hyper- and hypocapnia. Scanning laser arteriovenous passage time and  
6 capillary flow velocity data both reveal an apparent modulating effect of dorzolamide on  
7 perfusion deficits observed during placebo treatment, with both CO<sub>2</sub> imbibation and subsequent  
8 hyperventilation. Moreover, parity of responses was noted to exist between visual function and  
9 retinal perfusion. Similar findings were obtained with both blue field entoptic and Heidelberg  
10 retinal doppler flowmetry, which measured relative changes in microcirculation in the  
11 perimacular and midperipheral retina, respectively.

12 A pronounced association was also seen to exist between the absolute values for  
13 perifoveal contrast sensitivity (4 cpd) and retinal microcirculation during hyperventilation during  
14 dorzolamide treatment which was absent during placebo administration. The same phenomenon  
15 was observed with blue field entoptic measurements. In dorzolamide treated right eyes, blue  
16 field velocity was significantly associated with contrast sensitivity at 4 cpd during  
17 hyperventilation (ANOVA R=0.58; P=0.05), but no such association was observed in the non-  
18 treated left eyes (R=0.00; P=0.99) or placebo treated right eyes (R=0.09; P=0.77). In no  
19 instance was any significant association observed between perfusion and visual function during  
20 placebo treatment, whether considered in absolute terms or as a change from baseline.

21 An additional physiologic phenomenon noted during this study may be of considerable  
22 potential relevant to our understanding of the CO<sub>2</sub> circulatory link in the retina. Using high  
23 speed video angiography with the Rodenstock/Canon scanning laser ophthalmoscope, the

1 changes elicited by first breathing CO<sub>2</sub> enhanced air, following immediately by hyperventilation  
2 were observed. Arteriovenous passage time was monitored at the largest venules, one bifurcation  
3 from the optic nerve, and also at the smallest venules, equidistant from the disc. The former fill  
4 more slowly than the latter. During CO<sub>2</sub> breathing, arteriovenous passage time was significantly  
5 decreased in both large (p=0.005) and small (p=0.008) vessels. Upon hyperventilation, the large  
6 vessel filling rate returned to baseline, as expected (Figure 2). However, the small vessels  
7 responded in an inverse manner, filling even more rapidly than during CO<sub>2</sub> breathing (Figure 3).  
8 A similar dual response of large and small vessels to CO<sub>2</sub> has been observed in the brain, as  
9 discussed below.

10 Carbon dioxide, a ubiquitous and relatively benign product of human catabolism,  
11 promotes local vascular perfusion, facilitating its clearance and that of other waste products, and  
12 restoring nutrients to metabolically active tissue. The level of carbon dioxide in all tissues is  
13 dependent upon both metabolic and respiratory factors, and enzymes with extraordinarily high  
14 specific activity, the carbonic anhydrases, facilitate its movement between cells. Inhibitors of  
15 these enzymes tend to sequester carbon dioxide and thereby accentuate the endogenous effects  
16 of the gas on regional metabolism and blood flow.

17 The upward and downward changes in endogenous carbon dioxide induced  
18 experimentally are those a typical adult might naturally engender breathing beneath bedcovers  
19 or rapidly climbing stairs, respectively. The Dorzolamide treatment was associated with a  
20 stabilization of retinal perfusion during both hyper- and hypocapnia. Concerted responses were  
21 noted to exist between visual function and retinal perfusion under each breathing condition. A  
22 strong association between hyperventilatory perifoveal contrast sensitivity and retinal  
23 microcirculation noted during dorzolamide treatment was absent during placebo administration.

1           Similar findings have been obtained among a different study population receiving  
2 dorzolamide during hyperventilation without CO<sub>2</sub> preloading. Humphrey mean deviation (MD)  
3 values, under normal baseline breathing conditions, were significantly higher during dorzolamide  
4 treatment than during placebo treatment, and remained positive on dorzolamide and negative on  
5 placebo during CO<sub>2</sub> supplementation. Contrast sensitivity to a 30 Hz temporally-modulated 4  
6 cpd sine wave grating decreased significantly with CO<sub>2</sub> supplementation during placebo  
7 treatment (p=0.006), but showed no change from baseline values during dorzolamide treatment.  
8 The decrease in contrast sensitivity to the 1 cpd pattern during CO<sub>2</sub> supplementation more than  
9 doubled during hyperventilation during placebo treatment, but remained the same with  
10 dorzolamide treatment.

11           Many significant correlations were seen between the visual and perfusion changes  
12 induced by shifts in end-tidal CO<sub>2</sub> among these normal subjects, but only when dorzolamide was  
13 in use. One striking example was the strong association between the change in Heidelberg  
14 flowmetry from baseline breathing to hyperventilation, and the accompanying shift in contrast  
15 sensitivity for the spatial frequency 4 cpd. This association was absent during placebo treatment.  
16 A similar phenomenon was observed in a separate study group.

17           Thus, in view of the unexpected associations observed between visual function and the  
18 drug-independent intraocular pressure shifts induced by respiratory maneuvers, the hypothesis  
19 was pursued that combination with more neutral agents of intraocular pressure reduction might  
20 effect even greater circulatory and visual increase.

21           An array of pharmacologic agents presented themselves as options for combination  
22 therapy, and several of these have been tested, as outlined below. It was subsequently confirmed  
23 that a combination of a TCAI with an ocular hypotensive agent in a 0.001-3% solution or

1 suspension (or inotropic agent) will significantly enhance visual function in a manner heretofore  
2 unsuspected.

3 While dorzolamide appears to enhance visual function in normal subjects under normal  
4 conditions, and prevent visual decrease during perturbations of systemic carbon dioxide levels,  
5 it now has been found that combination with an additional ocular hypotensive agent such as a  
6 beta-blocker or the like greatly enhances the effect. During hypercapnia, the most pronounced  
7 modulating effect of dorzolamide was seen with the higher spatial frequency 4 cpd contrast  
8 pattern, which would be detected at the lowest threshold near the fovea. With ensuing  
9 hypocapnia, the modulating effect of dorzolamide on visual depression was seen most  
10 prominently with the lower spatial frequency 1 cpd contrast pattern, which would be detected  
11 at the lowest threshold peripheral to the fovea.

12 Hypocapnia is associated with decreased retinal perfusion. This perfusion decrease  
13 occurs despite a concomitant decrease in intraocular pressure, which would otherwise by  
14 definition, in the absence of other factors, increase retinal perfusion. Thus, the decrease in retinal  
15 sensitivity which accompanies hyperventilatory hypocapnia is clearly the consequence of factors  
16 which are neither provoked nor adequately compensated by aqueous hydrodynamic factors. The  
17 correlation analysis did not reveal any obvious association between pressure change and visual  
18 function change. The significantly greater degree of pressure reduction associated with  
19 dorzolamide therapy during hyperventilation may, however, be reasonably postulated to have a  
20 role in its observed visual protective effect under that condition.

21 Dorzolamide hydrochloride in combination with an ocular hypotensive or inotropic agent  
22 can enhance visual function in normal human eyes, under a range of physiologic conditions, via  
23 mechanisms which may be independent of or additive to the drug's known ocular hypotensive

1 action.

2  
3 Example 2 (Coadministration of TCAI with latanoprost, a topical prostaglandin derivative)

4 Latanoprost (Xalatan®) is a recently-released drug with a unique mechanism of action  
5 for reducing intraocular pressure. The drug greatly increases the outflow of aqueous humour  
6 from the eye through a pathway which normally acts as a minor accessory outflow pathway.  
7 Latanoprost's intrinsic effects on ocular circulation remain unknown, but the drug is capable of  
8 effecting substantial reductions of intraocular pressure, even in eyes which have a normal  
9 pressure level at baseline.

10 An experiment was conducted in which measurements of visual function and perimacular  
11 retinal circulation were obtained on normal eyes: 1) at baseline, prior to any drug administration,  
12 2) after 24 hours administration of three-times daily dorzolamide to the right eye only, and 3)  
13 after an additional 24-hour period of right eye treatment with dorzolamide at the same dosing  
14 rate, together with single bedtime applications of latanoprost to both eyes.

15 Intraocular pressure was not significantly changed in either eye on day 2, and was  
16 decreased by >30% on day 3 in both eyes. Perimacular leukocyte velocity (circulation in the  
17 retina near the macula) had increased to a supranormal level in the right eye only on day 3, with  
18 no other major differences from baseline in either eye.

19 Figure 4 shows the changes from baseline in visual function responses in both eyes as  
20 measured by the Humphrey perimeter. Visual function change increased in the right eye  
21 (dorzolamide only) with no change in the (untreated) left eye on day 2, consistent with prior  
22 study results. On day 3, however, when both eyes demonstrated a significant intraocular  
23 pressure reduction associated with bilateral latanoprost treatment, visual function had increased

1 3-fold in the TCAI plus latanoprost-treated right eye, and actually diminished to a comparable  
2 extent in the eye receiving latanoprost only.

3 These data illustrate dramatically a disproportionate synergistic effect of an independent  
4 intraocular pressure reducing drug (latanoprost) to the incremental positive effect of  
5 dorzolamide on retinal light sensitivity -- even when the cotherapeutic ocular hypotensive agent  
6 actually reduced visual function when used in the absence of the TCAI.

7  
8 Example 3 (Clinical response to cotherapy with dorzolamide plus carteolol in a 67 year-old  
9 female with an acute macular disorder)

10 A 67 year old Caucasian female with mild myopia presented to an eye clinic for a  
11 scheduled follow-up visit. She had a two year history of central visual blurring in the left eye,  
12 maintaining Snellen acuities of 20/20 in the right eye and 20/30 in the left, and intraocular  
13 pressures in the mid-teens in both eyes. She had no prior history of ocular trauma, diabetes, or  
14 other manifest ocular disease, but her clinical record confirmed the presence of a symmetric  
15 myopic disc configuration and peripapillary atrophy in both eyes. In addition, stereoscopic  
16 examination at the time revealed an idiopathic macular epiretinal membrane in the left eye, with  
17 mild drusen associated with irregularities of the retinal pigment epithelium in the papillomacular  
18 bundle of both eyes. Serial examination over the ensuing two-year period demonstrated relative  
19 stability of these findings, and an absence of any demonstrable pericentral visual field loss on  
20 Humphrey 30-2 thresholding perimetry in either eye.

21 Examination of both eyes yielded normal slit lamp findings, normal pupil reactions and  
22 ocular motility. The acuities were 20/25 in the right and 20/30 in the left, and the patient was  
23 aware of decreased central vision in her previously asymptomatic right eye. Ophthalmoscopic

1 examination of the left eye confirmed the presence of the peripapillary changes and epiretinal  
2 membrane noted previously. The right eye showed, in addition to the changes noted on the prior  
3 photographic record, temporal extension of the retinal pigment epithelial mottling just nasal to  
4 the fovea centralis. There was no associated hemorrhage, choroidal neovascular membrane, or  
5 edema present, although there were additional drusen.

6 Humphrey 30-2 visual fields were obtained. A dense pericentral scotoma was present  
7 in the right eye (Figure 5) which was not present in any of her prior visual field exams (Figure  
8 7). A detailed 10-degree visual field was immediately ordered (Figure 6) revealing a highly  
9 reproducible, non-neurologic, non-glaucomatous macular scotoma in a location  
10 pathophysiologically consistent with her zone of ophthalmoscopic change. The visual field  
11 defect did not respect the horizontal meridian, was not contiguous with the physiologic blind  
12 spot, and was severe in 9 contiguous loci, including both the superior and inferior temporal  
13 perifoveolar zones, but was immediately surrounded by areas of near-normal retinal sensitivity  
14 to light. These changes were consistent with early evolving age-related macular degeneration  
15 in the right eye.

16 The patient was placed on a daily regimen of carteolol 0.5% (a noncardioselective topical  
17 beta adrenergic antagonist with intrinsic sympathomimetic activity) and dorzolamide 2% (a  
18 topical carbonic anhydrase inhibitor) twice daily in the right eye with the intent of enhancing  
19 ocular perfusion. She was scheduled to return for repeat detailed 10-degree visual field  
20 assessment once this treatment regimen had been maintained for six weeks.

21 The follow-up visual field obtained within eleven weeks is shown in Figure 8. The dense  
22 scotoma in the temporal macula had completely resolved, and the adjacent macular threshold  
23 values in all sectors of the visual field were significantly improved. The Snellen acuity in the

1 treated right eye had returned to 20/20; the untreated left eye remained 20/30. Three months  
2 later the treated eye was still clear.

3 This example represents the first use of the combination of a topical carbonic anhydrase  
4 inhibitor (CAI) and non-CAI aqueous suppressant for the treatment of emerging age-related  
5 macular degeneration through the enhancement of ocular perfusion and visual function,  
6 according to the principles of the present invention. This novel combination therapy for apparent  
7 early-to-moderate macular degeneration was dramatically effective in this patient. This reversal  
8 of a new, dense, highly reproducible macular visual defect which arose concomitantly with a  
9 spatially-corresponding, new ophthalmoscopically-confirmed extension of macular degenerative  
10 fundus change, in a perimetrically-experienced subject with previously normal fields, is  
11 extraordinary.

12  
13 Example 4 (Clinical response to cotherapy with dorzolamide plus timolol in a 79 year-old  
14 female with a chronic macular disorder)

15 Shortly after the patient outcome described in Example 3, combination therapy was  
16 applied to another patient with a quite different history. This 79 year old female presented to an  
17 eye clinic. She had intraocular pressures of 16 mm Hg in the right eye and 14 Hg in the left.  
18 Despite having undergone cataract surgery in the right eye years earlier, the patient had a visual  
19 acuity of 20/400 in the right eye, with an acuity of 20/30 attributable to mild macular  
20 degeneration and cataract in the left eye. Ophthalmoscopic examination in the right eye revealed  
21 multiple drusen and scarring in the macular zone of the right eye, extending from the  
22 inferotemporal aspect of the macula into the fovea centralis. Visual fields were obtained  
23 immediately, and the patient proved to be highly reliable, with very few fixation losses or false

1 positive or negative testing errors. Her left visual field was normal, but the right demonstrated  
2 a dense pericentral scotoma (Figure 9) corresponding to the zone of macular scarring noted  
3 ophthalmoscopically.

4 The patient was placed on a twice-daily regimen of 2 %dorzolamide plus timolol 0.5%  
5 in the right eye. She returned 12 weeks later for repeat visual field testing. Her intraocular  
6 pressures were 11 mmHg in the right eye and 12 Hg in the left, representing a >30% reduction  
7 in pressure from the previously normal level in the right eye. Her visual acuity was unchanged  
8 in the left eye, and improved to 20/200 in the right.

9 Most remarkably, despite her retained scarring in the perimacular zone on  
10 ophthalmoscopy, her retinal sensitivity to light had increased over 10,000-fold in the region  
11 associated with the old retinal scar according to the logarithmic scale of the Humphrey perimeter  
12 (Figure 10). The anatomy of the retina was of course still distorted, accounting for her only  
13 marginal Snellen acuity improvement. However, the previously dysfunctional retinal tissue  
14 within the degenerative macula now appeared to be generating appropriate neural responses to  
15 local light stimuli. The patient was subjectively aware of this visual improvement.

16 The above examples demonstrate the apparent ability of cotherapy of TCAI with a variety  
17 of different independent pharmacologic ocular hypotensive agents to generate remarkable  
18 improvements in central retinal light sensitivity in normal, acutely diseased, and chronically  
19 diseased eyes. The effect is consistent with that hypothesized on the basis of the detailed analysis  
20 of the placebo-controlled double-masked crossover study described at the beginning of this  
21 summary.

22 The carbonic anhydrase inhibitor may be administered as a 0.01-5%, preferably a 0.5 to  
23 2% solution or suspension and the ocular hypotensive agent as a 0.001% to 6.0% solution or

1 suspension in an ophthalmologically acceptable carrier. Such agents include, but not be limited  
2 to beta blockers (betaxolol, timolol, optipranolol, levobunolol, metapranolol, carteolol, and the  
3 like), miotic agents (pilocarpine, carbachol, phospholine iodide, and the like), adrenergic agonists  
4 (iopidine, brimonidine, epinephrine, dipivephrin, and the like), prostaglandin derivatives  
5 (latanoprost and the like), and related compounds directed toward the reduction of intraocular  
6 pressure, plus agents effective in the enhancement of carotid perfusion pressure, including a  
7 range of oral and sublingual systemic drugs intended to improve cardiac contractility or decrease  
8 carotid or ophthalmic arterial vascular resistance.

9         Although the invention has been described with reference to specific embodiments, this  
10 description is not meant to be construed in a limited sense. Various modifications of the  
11 disclosed embodiments, as well as alternative embodiments of the inventions will become  
12 apparent to persons skilled in the art upon the reference to the description of the invention. It  
13 is, therefore, contemplated that the appended claims will cover such modifications that fall within  
14 the scope of the invention.

## 1 I CLAIM:

2 1. A method of treating macular disorders comprising applying a composition of carbonic  
3 anhydrase inhibitor in combination with an ocular hypotensive agent in an amount sufficient to  
4 improve visual function.

5  
6 2. The method of claim 1 wherein said carbonic anhydrase inhibitor is selected from the group  
7 consisting of dorzolamide and brinzolamide and their mixtures.

8  
9 3. The method of claim 1 wherein said ocular hypotensive agent is selected from the group  
10 consisting of beta blockers, miotic agents, adrenergic agonist, prostaglandin derivatives, cartoid  
11 perfusion pressure agents, and oral and sublingual systemic agents to improve cardiac  
12 contractility or decrease cartoid or ophthalmic arterial vascular resistance.

13  
14 4. The method of claim 1 wherein said carbonic anhydrase inhibitor is dorzolamide.

15  
16 5. The method of claim 1 wherein said carbonic anhydrase inhibitor is .01% to 5% dorzolamide  
17 and said ocular hypotensive agent is .001% to 6%.

18  
19 6. A composition for treating macular disorders comprising a pharmologically effective amount  
20 of a carbonic anhydrase inhibitor in combination with a pharmologically effective amount of an  
21 ocular hypotensive agent.

22  
23 7. The composition of claim 6 wherein said carbonic anhydrase inhibitor is selected from the

1 group consisting of dorzolamide and brinzolamide and their mixtures.

2

3 8. The composition of claim 6 wherein said ocular hypotensive agent is selected from the group  
4 consisting of beta blockers, miotic agents, adrenergic agonist, prostaglandin derivatives, cartoid  
5 perfusion pressure agents, a nd oral and sublingual systemic agents to improve cardiac  
6 contractility or decrease cartoid or ophthalmic arterial vascular resistance.

7

8 9. The composition of claim 6 wherein said carbonic anhydrase inhibitor is dorzolamide.

9

10 10. The composition of claim 6 wherein said carbonic anhydrase inhibitor is .01% to 5%  
11 dorzolamide and said ocular hypotensive agent is .001% to 6%.

12




Fig. 1A




Fig. 1B




Fig. 2




Fig. 3




Fig. 4

Central 30-2 Threshold Test

Fixation Monitor: Gaze/Blindspot

Fixation Target: Central

Fixation Losses: 6/6

False POS Errors: 1%

False NEG Errors: 7%


Test Duration: 09:18

Fovea: OFF

Stimulus: III, White  
Background: 31.5 ASB  
Strategy: SITA-Standard

Pupil Diameter: 4.7mm  
Visual Acuity:  
RX: +3.00 DS DC X

Date: 03-31-98  
Time: 8:50 AM  
Age: 66



2/7

Fig. 5

Central 10-2 Threshold Test

Fixation Monitor: Gaze/Blindspot

Fixation Target: Central

Fixation Losses: 7/7

False POS Errors: 5%

False NEG Errors: 4%

Test Duration: 09:04

Fovea: OFF

Stimulus: III, White  
Background: 31.5 ASB  
Strategy: SITA-Standard

Pupil Diameter: 4.5mm  
Visual Acuity:  
RX: +3.00 DS DC X

Date: 03-31-98  
Time: 10:18 AM  
Age: 66




Fig. 6

CENTRAL 30-2 THRESHOLD TEST  
THRESHOLD GRAYSTONE 4/7




Fig. 7







INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/04879

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) :A61K 31/385 US CL :514/439, 912 According to International Patent Classification (IPC) or to both national classification and IPC														
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/439, 912 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)														
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>														
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
X, P	US 5,789,435 A (HARRIS ET AL) 04 August 1998, see the entire document.	1-10												
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.														
<table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>*A* document defining the general state of the art which is not considered to be of particular relevance</td> <td>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>*E* earlier document published on or after the international filing date</td> <td>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>*Z* document member of the same patent family</td> </tr> <tr> <td>*O* document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>*P* document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family	*O* document referring to an oral disclosure, use, exhibition or other means		*P* document published prior to the international filing date but later than the priority date claimed	
* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family													
*O* document referring to an oral disclosure, use, exhibition or other means														
*P* document published prior to the international filing date but later than the priority date claimed														
Date of the actual completion of the international search 30 APRIL 1999		Date of mailing of the international search report 14 MAY 1999												
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer FREDERICK KRAS Telephone No. (703) 308-1235 <i>Fred Krass</i>												